We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Transgene is to Acquire Immuno-Monitoring Activities of Indicia Biotechnology
News

Transgene is to Acquire Immuno-Monitoring Activities of Indicia Biotechnology

Transgene is to Acquire Immuno-Monitoring Activities of Indicia Biotechnology
News

Transgene is to Acquire Immuno-Monitoring Activities of Indicia Biotechnology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Transgene is to Acquire Immuno-Monitoring Activities of Indicia Biotechnology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Transgene SA announces that its affiliate Platine Pharma Services SAS (Platine), specialized in providing immune-monitoring services (quantitative measurement of immune response to products that stimulate the immune system) is acquiring immuno-monitoring activities of Indicia Biotechnology.

The acquired activities are the development of immunoassays as well as the proprietary platform Immunoline™ dedicated to the immunogenicity risk assessment of biologicals.
This transaction will be a contribution in kind whereby Indicia Biotechnology will dispose of the aforementioned assets to Platine in exchange for new shares in the capital of the latter. It will be submitted to the shareholders’ approval of both companies on July 31, 2013.

“Transgene is delighted to support this transaction which will allow Platine to accelerate its development through access to new businesses and new clients” stated Stephane Boissel, Executive VP of Transgene and Director of the Board of Platine. He added: “Transgene does not intend to remain a major shareholder of Platine since its business model, which is centered on services, is far from our own. Providing Platine with an opportunity to grow its business whilst diluting our shareholding is therefore totally in line with Transgene’s strategic intent”.

Advertisement